This is a preview of subscription content, log in via an institution to check access.
Reference
MHRA. Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment. Drug Safety Update 14: 7-8, No. 3, Oct 2020. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/928774/Oct-2020-DSU-PDF.pdf
Rights and permissions
About this article
Cite this article
Niraparib: severe hypertension and posterior reversible encephalopathy. Reactions Weekly 1829, 5 (2020). https://doi.org/10.1007/s40278-020-85595-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-85595-0